Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft-tissue tumors. 3rd Interdisciplinary Consensus Conference "PET in Oncology": Results of the Bone and Soft-Tissue Study Group;Klinische Wertigkeit der Positronenemissionstomographie (PET) in der Diagnostik der Knochen- und Weichteiltumore - 3. Interdisziplinäre Konsensuskonferenz "PET in der Onkologie". Ergebnisse der Arbeitsgruppe Knochen- und Weichteiltumore

Chirurg

Volumn 72, Issue 9, 2001, Pages 1071-1077

  Franzius, Christiane ^a   Schulte, M ^b   Hillmann, A ^a   Winkelmann, W ^a   Jurgens H ^a   Bockisch, A ^c   Schober, O ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Bone tumors; FDG PET; Osteosarcomas; Sarcomas; Soft tissue tumors

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGE; BONE TUMOR; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIFFERENTIAL DIAGNOSIS; EVALUATION; HUMAN; METASTASIS; OSTEOSARCOMA; PROGNOSIS; SARCOMA; SCINTISCANNING; SOFT TISSUE TUMOR; TUMOR RECURRENCE;

AGE FACTORS; BONE NEOPLASMS; CHILD; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035464534     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001040170078     Document Type: Article

References (52)

1. Adler LP, Blair HF, Makley JT, Williams RP, et al (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32: 1508
2. Aoki J, Watanabe H, Shinozaki T, Tokunaga M, et al (1999) FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 23: 603
3. Chapot C, Roubaine Z al, Kirsch CM (1998) Positron emission tomography and bone scintigraphy of an osteoclast metastasis. Nuklear-medizin 37: 183
4. Cook GJR, Maisey MN, Fogelman I (1997) Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med 38: 1495
5. Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, et al (1996) Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-(F-18)fluoro-2-deoxy-D-glucose. Radiology 200: 243
6. Del Barrio CA, Delgado M, Andree RM, Castejón MJP, et al (1999) Positron emission tomography in bone disease. Oncologia 22: 33
7. Doss M (1997) Unusual high uptake of fluoro-2-deoxy-D-glucose on PET scanning of a benigne paravertebral mass. Thorac Cadiovasc Surg 45: 310
8. Eary JF, Conrad EU, Bruckner JD, Fope A, et al (1998) Quantitative (F-18)fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 4: 1215
9. Eary JF, Mankoff DA (1998) Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 39: 250
10. Eary JF, Conrad EU (1999) Positron emission tomography in grading soft tissue sarcoma. Semin Musc Radiol 3: 135
11. Fletcher BD (1991) Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. Am J Roentgenol 157: 825
12. Fletcher BD (1997) Imaging pediatric bone sarcomas: Diagnosis and treatment-related issues. Radiol Clin North Am 35: 1477
13. Focacci C, Lattanzi R, Iadeluca ML, Campioni P (1998) Nuclear medicine in primary bone tumors. Eur J Radiol 27 [Suppl 1]: 123
14. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, Eary JF (2000) (F-18)fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 6: 1279
15. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12: 479
16. Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O (2000) Evaluation of chemotherapy response in primary bone tumors with F-18-FDG-PET in comparison with histologically assessed tumor necrosis. Clin Nucl Med 25: 874
17. Franzius C, Sciuk J, Daldrup-Link HE, Jürgens H, Schober O (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur J Nucl Med 27: 1305
18. Garcia JR, Kim EE, Wong FCL, Korkmaz M, et al (1996) Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 37: 1476
19. Griffeth LK, Dehdashti F, McGuire AH, McGuire DJ, et al (1992) PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 182: 185
20. Hain SF, O'Doherty MJ, Lucas JD, Smith MA (1999) Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma. Nucl Med Commun 20: 845
21. Hicks RJ (1997) Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. Acta Orthop Scand 68 [Suppl 273]: 25
22. Hoegerle S, Juengling F, Otte A, Altehoefer C, et al (1998) Combined FDG/fluoride whole body PET: a feasible two-in-one approach to cancer imaging. Radiology 209: 253
23. Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, et al (1993) Whole body skeletal imaging with (F-18)fluoride ion and PET. J Comput Assist Tomogr 17: 34
24. Joncs DN, McCowage GB, Sostman HD, Brizel DM, et al (1996) Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37: 1438
25. Kent DL, Larson EB (1992) Disease, level of impact, and quality of reserch methods. Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. Invastigative Radiol 27: 245
26. Kern KA, Brunetti A, Norton JA, Chang AE, et al (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 29: 181
27. Kole AC, Nieweg OE, Ginkel RJ van, Pruim J, et al (1997) Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using (F-18)fluorodeoxyglucose. Ann Surg Oncol 4: 57
28. Kole AC, Nieweg OE, Hoekstra HJ, Horn JR van, et al (1998) Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 39: 810
29. Kole AC, Plaat BEC, Hoekstra HJ, Vaalburg W, Molenaar WM (1999) FDG and L-[1-(11)C]-tyrosine imaging of soft-tissue tumors before and after therapy. J Nucl Med 40: 381
30. Konsensus - Onko-PET, DGN-Nachrichten (1997) 2. interdisziplinäre Konsensus-Konferenz PET bei onkologischen Fragestellungen. Nuklearmedizin 36: 45
31. Kosuda S, Wahl RL, Grossman HB (1997) Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET. Ann Nucl Med 11: 263
32. Leskinen S, Lapela M, Lindholm P, Minn H (1997) Metabolic imaging by positron emission tomography in oncology. Ann Med 29: 271
33. Lodge MA, Lucas JD, Marsden PK, Cronin BF, et al (1999) A PET study of (18)FDG uptake in soft tissue masses. Eur J Nucl Med 26: 22
34. Lucas JD, O'Doherty MJ, Wong JCH, Bingham JB, et al (1998) Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcoma. J Bone Joint Surg Br 80: 441
35. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, et al (1999) Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 86: 550
36. Miraldi F, Adler LP, Faulhaber P (1997) PET imaging in soft tissue sarcomas. Cancer Treat Res 91: 51
37. Nieweg OE, Pruim J, Hoekstr HJ, Paans AMJ, et al (1994) Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med 35: 90
38. Nieweg OE, Pruim J, Ginkel RJ van, Hoekstra HJ, et al (1996) Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 37: 257
39. Reske SN, Bares R, Büll U, Guhlmann A, et al (1996) Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 35: 42
40. Schiepers C, Hoh CK (1998) Positron emission tomography as a diagnostic tool in oncology. Eur Radiol 8: 1481
41. Schirrmeister H, Kotzerke J, Rentschier M, Träger H, et al (1998) Die Positronenenissionstomographie des Skelettsystems mit F-18-Na: Häufigkeit, Befundmuster und Verteilung benigner Veränderungen. Fortschr Röntgenstr 169: 310
42. Schirrmeister H, Rentschier M, Kotzerke J, Diederichs CG, Reske SN (1998) Imaging the normal skeletal system with 18F Na-PET compared with conventional skeletal scintigraphy using Tc99m-MDP. Fortschr Röntgenstr 168: 451
43. Schirrmeister H, Guhlmann A, Eisner K, Kotzerke J, et al (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 40: 1623
44. Schirrmeister H, Guhlmann A, Elsner K, Nüssle K, et al (1999) Die Positronenemissionstomographie des Skelettsystems mit 18FNa: Häufigkeit, Befundmuster und Verteilung von Skelettmetastasen. Röntgenpraxis 52: 19
45. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, et al (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17: 2381
46. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, et al (1999) Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible? Eur J Nucl Med 26: 599
47. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, et al (1999) Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET. J Nucl Med 40: 1637
48. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, et al (2000) Grading of tumors and tumorlike lesions of bone: evaluation by 2-(fluorine-18)-fluoro-2deoxy-D-glucose positron emission tomography. J Nucl Med 41: 1695
49. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A, Strauss LG, et al (1999) Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 19: 1343
50. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, et al (2000) Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 231: 380
51. Van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, et al (1996) FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 37: 984
52. Watanabe H, Shinozaki T, Yanagawa T, Aoki J, et al (2000) Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG as an aid to preoperative planning. J Bone Joint Surg Br 82: 760